Covered recipient · General Payments record
JOHN LEUNG
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$11,339.06
78 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,251.00 | 2 |
| Education | $4,000.00 | 1 |
| Food and Beverage | $1,518.56 | 73 |
| Travel and Lodging | $569.50 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Intuitive Surgical, Inc. | $4,583.60 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,941.17 | 7 |
| GENZYME CORPORATION | $1,553.01 | 8 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $220.49 | 11 |
| AstraZeneca Pharmaceuticals LP | $210.59 | 10 |
| Regeneron Healthcare Solutions, Inc. | $155.49 | 6 |
| kaleo, Inc. | $145.26 | 7 |
| GlaxoSmithKline, LLC. | $144.51 | 7 |
| Genentech USA, Inc. | $88.91 | 4 |
| CSL Behring | $85.84 | 3 |
| PFIZER INC. | $72.39 | 4 |
| Celgene Corporation | $46.88 | 2 |
| Braintree Laboratories, Inc. | $27.97 | 1 |
| AIMMUNE THERAPEUTICS, INC. | $18.96 | 1 |
| Novartis Pharmaceuticals Corporation | $15.10 | 1 |
| USWM, LLC | $15.00 | 1 |
| ALK-Abello, Inc | $13.89 | 1 |
Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JOHN LEUNG
NPI 1447328711 · CMS profile ID 803106
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
BOSTON, MA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1447328711?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JOHN LEUNG, NPI 1447328711, CMS profile ID 803106. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447328711?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). JOHN LEUNG, NPI 1447328711, CMS profile ID 803106. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447328711?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- JOHN LEUNG, NPI 1447328711, CMS profile ID 803106, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1447328711?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
78 matching records · $11,339.06 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–78 of 78.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $12.52 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834325087 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.50 | 04/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849979629 | CMS |
| ALK-Abello, Inc | $13.89 | 04/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809207559 | CMS |
| Genentech USA, Inc. | $20.12 | 04/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835929945 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,850.00 | 04/22/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820046183 | CMS |
| GENZYME CORPORATION | $21.73 | 04/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843624701 | CMS |
| CSL Behring | $35.74 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820251375 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.19 | 04/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850036785 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.88 | 04/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834341923 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $17.07 | 03/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820046179 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.33 | 03/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834347327 | CMS |
| Braintree Laboratories, Inc. | $27.97 | 03/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 805251429 | CMS |
| CSL Behring | $23.86 | 03/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820251345 | CMS |
| GENZYME CORPORATION | $23.70 | 03/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843624645 | CMS |
| Genentech USA, Inc. | $21.51 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835929941 | CMS |
| kaleo, Inc. | $19.63 | 03/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832122277 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.45 | 03/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850404895 | CMS |
| AstraZeneca Pharmaceuticals LP | $33.60 | 03/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834327299 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.90 | 02/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834337417 | CMS |
| GENZYME CORPORATION | $24.85 | 02/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843624621 | CMS |
| PFIZER INC. | $14.39 | 02/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833377401 | CMS |
| GlaxoSmithKline, LLC. | $23.23 | 01/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 802282265 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.26 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834347345 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.86 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850422811 | CMS |
| AIMMUNE THERAPEUTICS, INC. | $18.96 | 01/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850425591 | CMS |
| GENZYME CORPORATION | $16.50 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 843624613 | CMS |
| Genentech USA, Inc. | $23.98 | 01/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835929939 | CMS |
| CSL Behring | $26.24 | 01/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820251257 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $5,466.07 | 5 |
| PY2025 | Principal investigator | $520,247.61 | 100 |
| PY2024 | Principal investigator | $307,044.91 | 13 |
| PY2023 | Principal investigator | $281,618.72 | 18 |
| PY2022 | Recipient | $2,853.32 | 4 |
| PY2022 | Principal investigator | $353,342.22 | 36 |
| PY2021 | Recipient | $1,824.42 | 4 |
| PY2021 | Principal investigator | $262,724.24 | 24 |
| PY2020 | Recipient | $1,650.00 | 1 |
| PY2020 | Principal investigator | $263,306.55 | 29 |
| PY2019 | Principal investigator | $150,843.60 | 25 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
105 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $721.06 | 12/11/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184274568 |
| Principal investigator 1 | ABBVIE INC. | $1,562.00 | 12/04/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202528946 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,825.12 | 12/04/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184269147 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $17,106.00 | 12/04/2025 | Non-covered Recipient Entity Boston Specialists | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226122586 |
| Principal investigator 1 | ABBVIE INC. | $8,155.65 | 11/26/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202525668 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,124.04 | 11/25/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184264491 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $8,141.50 | 11/21/2025 | Non-covered Recipient Entity Boston Food Allergy Center Llc | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1235998524 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,871.70 | 11/20/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184263629 |
| Principal investigator 1 | ABBVIE INC. | $349.70 | 11/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202524379 |
| Principal investigator 1 | ABBVIE INC. | $5,718.55 | 11/07/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202523583 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,921.74 | 11/07/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184258925 |
| Principal investigator 1 | ABBVIE INC. | $201.10 | 11/04/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202521049 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $187.00 | 10/30/2025 | Non-covered Recipient Entity Boston Specialists | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226128021 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $721.06 | 10/29/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184253626 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,363.86 | 10/23/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184252574 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $40.00 | 10/23/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223287603 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,813.00 | 10/17/2025 | Non-covered Recipient Entity Boston Specialists | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226128017 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,624.44 | 10/16/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184250633 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $392.00 | 10/15/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286773 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $553.00 | 10/15/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286861 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $392.00 | 10/15/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286863 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,429.00 | 10/15/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286865 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $553.00 | 10/15/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223286867 |
| Principal investigator 1 | ABBVIE INC. | $4,995.10 | 10/09/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202515175 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,363.86 | 10/09/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184248946 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19,232.78 | 10/08/2025 | Non-covered Recipient Entity BOSTON SPECIALISTS | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190307909 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,650.24 | 10/03/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184244623 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $80.00 | 09/25/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223285901 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,921.74 | 09/23/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184241612 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,650.24 | 09/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184240444 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,429.00 | 09/17/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223285530 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,120.70 | 09/15/2025 | Non-covered Recipient Entity BOSTON SPECIALISTS | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190308326 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,765.22 | 09/12/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184236536 |
| Principal investigator 1 | ABBVIE INC. | $12.00 | 09/05/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202510180 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,481.00 | 09/05/2025 | Non-covered Recipient Entity Boston Specialists | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226128009 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $721.06 | 09/04/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184235157 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,642.80 | 08/26/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184230309 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $80.00 | 08/26/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223284607 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $86.00 | 08/20/2025 | Non-covered Recipient Entity Boston Specialists | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226128013 |
| Principal investigator 1 | ABBVIE INC. | $794.55 | 08/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202504989 |
| Principal investigator 1 | ABBVIE INC. | $139.35 | 08/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202504995 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,363.86 | 08/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184228299 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,481.00 | 08/13/2025 | Non-covered Recipient Entity Boston Specialists | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226128006 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,071.00 | 08/11/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223284073 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,825.12 | 08/07/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184226121 |
| Principal investigator 1 | ABBVIE INC. | $3,716.60 | 08/06/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202502454 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $21,194.48 | 08/01/2025 | Non-covered Recipient Entity BOSTON SPECIALISTS | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista | No dispute reported | 06/30/2026 | 1190308328 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 08/01/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223283347 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,746.86 | 07/31/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184222810 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $193.00 | 07/23/2025 | Non-covered Recipient Entity Boston Specialists | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226128001 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,921.74 | 07/22/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184217713 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $11,765.22 | 07/17/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184217038 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,071.00 | 07/16/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223282680 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,442.12 | 07/10/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184214340 |
| Principal investigator 1 | ABBVIE INC. | $3,311.60 | 07/08/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202497058 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,825.12 | 07/04/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184212821 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,481.00 | 07/02/2025 | Non-covered Recipient Entity Boston Specialists | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226127996 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $903.38 | 06/24/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184210630 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,071.00 | 06/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223281518 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,071.00 | 06/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223281520 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,163.18 | 06/12/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184206217 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,921.74 | 06/05/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184204143 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $63.00 | 06/04/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223280592 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $55.00 | 06/04/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223280594 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 06/04/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223280596 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $51.00 | 06/04/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223280598 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,921.74 | 05/28/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184198861 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,921.74 | 05/15/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184194615 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,197.00 | 05/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279592 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $524.00 | 05/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279594 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,071.00 | 05/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279596 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,071.00 | 05/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223279598 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,642.80 | 05/08/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184193731 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $322.61 | 05/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184119687 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $4,361.40 | 05/01/2025 | Covered Recipient Physician | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE) | No dispute reported | 06/30/2026 | 1184119689 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $41,706.13 | 04/28/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184190639 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,186.44 | 04/23/2025 | Non-covered Recipient Entity LONG ISLAND REGIONAL ARTHRITIS AND OSTEOPOROSIS CARE, PC | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) | No dispute reported | 06/30/2026 | 1185544473 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,429.00 | 04/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278460 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $524.00 | 04/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278462 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,529.00 | 04/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278464 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,107.00 | 04/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278466 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $658.00 | 04/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278468 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $658.00 | 04/18/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223278470 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 04/04/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER | A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) | No dispute reported | 06/30/2026 | 1202474391 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13,775.00 | 04/02/2025 | Non-covered Recipient Entity Boston Specialists | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226127992 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $261.43 | 04/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184119683 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $264.88 | 04/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184119685 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $650.00 | 04/01/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184180850 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,198.00 | 03/25/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184178868 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,149.94 | 03/20/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A U.S. REGISTRY OF EOSINOPHILIC ESOPHAGITIS PATIENTS TREATED WITH DUPIXENT AS STANDARD OF CARE | No dispute reported | 06/30/2026 | 1184175018 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,197.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276469 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,197.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276471 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,471.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276483 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,487.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276485 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $524.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276487 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,429.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276489 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,529.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276491 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,107.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276493 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,471.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276495 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,487.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276497 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $524.00 | 03/14/2025 | Non-covered Recipient Entity BOSTON FOOD ALLERGY CENTER LLC | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET | No dispute reported | 06/30/2026 | 1223276499 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $10,954.00 | 02/12/2025 | Non-covered Recipient Entity Boston Specialists | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235998518 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $255.75 | 02/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184119681 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $56,946.64 | 01/17/2025 | Non-covered Recipient Entity BOSTON SPECIALISTS | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING) | No dispute reported | 06/30/2026 | 1185544471 |
| Principal investigator 1 | Celgene Corporation | $19,363.00 | 01/13/2025 | Non-covered Recipient Entity Boston Food Allergy Center Llc | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1222307137 |